New Frontiers in Therapeutics for Interstitial Lung Diseases
- PMID: 36735934
- PMCID: PMC10112432
- DOI: 10.1164/rccm.202206-1035RR
New Frontiers in Therapeutics for Interstitial Lung Diseases
Comment on
-
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.Eur Respir J. 2021 May 27;57(5):2002559. doi: 10.1183/13993003.02559-2020. Print 2021 May. Eur Respir J. 2021. PMID: 33214209 Free PMC article. Clinical Trial.
-
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30. Lancet Respir Med. 2021. PMID: 33798455 Clinical Trial.
-
Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial.JAMA. 2021 May 11;325(18):1841-1851. doi: 10.1001/jama.2021.4956. JAMA. 2021. PMID: 33974018 Free PMC article. Clinical Trial.
References
-
- Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, et al. CleanUP-IPF Investigators of the Pulmonary Trials Cooperative Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial. JAMA . 2021;325:1841–1851. - PMC - PubMed
-
- Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet . 2012;380:660–667. - PubMed
-
- Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med . 2016;194:265–275. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical